SIGLEC7 and central nervous system cancer: Based on the TCGA and CGGA databases, we analyzed the relationship between the expression level of SIGLEC7 and clinicopathological features of glioma patients, including histological diagnosis, WHO grade, gender, age, IDH mutation status, 1p/19q co-deletion status, MGMT promoter methylation status, and pathological subtypes, and described the patients’ relevant survival outcomes (Figures 1A, B).